News

Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC

04/21/2023

Derek Cowsert

Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.

Osimertinib demonstrated modest...

04/21/2023

Oncology

News

EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population

03/09/2023

Derek Cowsert

The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.

The prevalence of EGFR mutations...

03/09/2023

Oncology

News

EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population

03/09/2023

Derek Cowsert

The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.

The prevalence of EGFR mutations...

03/09/2023

Oncology

News

PD-L1 Score Demonstrates Value as Prognostic Biomarker in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

01/18/2023

Derek Cowsert

Study finds PD-L1 scores exhibit value in predicting survival rates in patients with early stage EFGR-mutated non-small cell lung cancer.

Study finds PD-L1 scores exhibit...

01/18/2023

Oncology

News

Somatic Missense Mutations Identified as Promising Targets of Future Treatment for NSCLC

08/29/2022

Derek Cowsert

Study findings reveal 4 somatic missense mutations as rare genetic markers for NSCLC, making them promising targets for study and development of future treatments.

Study findings reveal 4 somatic...

08/29/2022

Oncology

News

TP53 Alterations Predict Rapid Treatment Resistant Evolution in Patients With EFGR-Mutated NSCLC

08/09/2022

Derek Cowsert

Study findings reveal TP53 alterations were associated with rapid progression of treatment resistance evolution regardless of treatment mechanism in patients with EFGR-mutated NSCLC.

Study findings reveal TP53...

08/09/2022

Oncology

News

Amivantamab Associated With Improved Outcomes vs Real-World Therapies in EGFR-Mutated NSCLC

07/07/2022

Janelle Bradley

Among patients with EGFR-mutated advanced NSCLC whose disease progressed after platinum-based chemotherapy, treatment with amivantamab is associated with improved outcomes vs real-world therapies, according to a recent study.

Among patients with EGFR-mutated...

07/07/2022

Oncology

News

Aumolertinib vs Gefitinib as First-Line Treatment for Patients With EFGR-Mutated NSCLC

07/06/2022

Derek Cowsert

Study findings reveal first-line treatment with aumolertinib was associated with improved survival outcomes compared to gefitinib in patients with EFGR-mutated NSCLC.

Study findings reveal first-line...

07/06/2022

Oncology

News

First-Line Bevacizumab Plus Erlotinib Prolongs PFS in EGFR-Mutated Advanced NSCLC: BEVERLY Trial

06/20/2022

Yvette C. Terrie, BSPharm, RPh

Yvette C. Terrie, BSPharm, RPh ...

Bevacizumab added to erlotinib improved PFS among Italian patients with EGFR-mutated NSCLC, according to results from the phase 3 BEVERLY trial.

Bevacizumab added to erlotinib...

06/20/2022

Oncology

News

Osimertinib Plus Bevacizumab Fails to Improve PFS Among Patients With NSCLC Harboring EGFR Mutations

06/20/2022

Yvette C. Terrie, BSPharm, RPh

Yvette C. Terrie, BSPharm, RPh ...

In a phase 2 study, osimertinib plus bevacizumab failed to improve PFS vs osimertinib monotherapy for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR mutations.

In a phase 2 study, osimertinib...

06/20/2022

Oncology

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology